The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles

Pharmaceutical Research

Volumn 27, Issue 9, 2010, Pages 1949-1964

  Trevaskis, Natalie L ^a   Shanker, Ravi M ^b   Charman, William N ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

^b PFIZER INC   (United States)

Author keywords

absorption; CETP inhibitor; intestine; lipid; lipid based delivery system; lipoprotein; lymphatic transport

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHYLOMICRON; CP 524515; CP 532623; CP532623; DECANOIC ACID; LIPOPROTEIN; LYMPH LIPOPROTEIN; OLEIC ACID; PHOSPHOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; EMULSION; FLOW CYTOMETRY; LIPID SOLUBILITY; LIPID TRANSPORT; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; STEADY STATE; ULTRACENTRIFUGATION;

AMINOQUINOLINES; ANIMALS; BIOLOGICAL TRANSPORT; CARBAMATES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DESIGN; FLOW CYTOMETRY; LIPOPROTEINS; LYMPH; MALE; MOLECULAR STRUCTURE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 77955472478     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0199-2     Document Type: Article

References (38)

1. RW Clark RB Ruggeri D Cunningham MJ Bamberger 2006 Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action J Lipid Res 47 537 52 10.1194/jlr.M500349-JLR200 1:CAS:528:DC%2BD28XisVagurY%3D 16326978 (Pubitemid 43345595)
2. JA Kuivenhoven GJ de Grooth H Kawamura AH Klerkx F Wilhelm MD Trip, et al. 2005 Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia Am J Cardiol 95 1085 8 10.1016/j.amjcard.2004.12.064 1:CAS:528:DC%2BD2MXjsVensb0%3D 15842977 (Pubitemid 40544314)
3. K El Harchaoui WA van der Steeg ES Stroes JJ Kastelein 2007 The role of CETP inhibition in dyslipidemia Curr Atheroscler Rep 9 125 33 10.1007/s11883-007-0008-5 1:CAS:528:DC%2BD2sXhtVOqurnK 17877921 (Pubitemid 47376983)
4. EJ Schaefer BF Asztalos 2006 Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction Curr Opin Lipidol 17 394 8 10.1097/01.mol.0000236364.63840.d8 1:CAS:528:DC%2BD28Xms1yrtbo%3D 16832162 (Pubitemid 44079476)
5. LG Howes K Kostner 2007 The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism Expert Opin Investig Drugs 16 1509 16 10.1517/13543784.16.10.1509 1:CAS:528:DC%2BD2sXhtFekt7rF 17922616 (Pubitemid 350028403)
6. NL Trevaskis CL McEvoy MP McIntosh GA Edwards RM Shanker WN Charman, et al. 2010 The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524, 515 and CP532, 623) Pharm Res 27 878 93 10.1007/s11095-010-0083-0 1:CAS:528: DC%2BC3cXjtVWrsLo%3D 20221896
7. WN Charman VJ Stella 1986 Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules Int J Pharm 34 175 8 10.1016/0378-5173(86)90027-X 1:CAS:528:DyaL2sXmtVOgtw%3D%3D
8. BM Johnson W Chen RT Borchardt WN Charman CJH Porter 2003 A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum J Pharmacol Exp Ther 305 151 8 10.1124/jpet.102.045328 1:CAS:528:DC%2BD3sXis1antbc%3D 12649363 (Pubitemid 36373845)
9. NL Trevaskis CJH Porter WN Charman 2005 Bile increases intestinal lymphatic drug transport in the fasted rat Pharm Res 22 1863 70 10.1007/s11095-005-6808-9 1:CAS:528:DC%2BD2MXhtFChs7nO 16132351 (Pubitemid 41504339)
10. NL Trevaskis CJH Porter WN Charman 2006 The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport J Pharmacol Exp Ther 316 881 91 10.1124/jpet.105.094094 1:CAS:528:DC%2BD28XhtlWqtL8%3D 16249368 (Pubitemid 43131018)
11. DB Zilversmit 1965 The composition and structure of lymph chylomicrons in dog, rat, and man J Clin Invest 44 1610 22 10.1172/JCI105267 1:CAS:528:DyaF2MXkvVaktb8%3D 5840531
12. P Gershkovich A Hoffman 2005 Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability Eur J Pharm Sci 26 394 404 10.1016/j.ejps.2005.07.011 1:CAS:528:DC%2BD2MXhtFKns73I 16140514 (Pubitemid 41551573)
13. Charman WN, Stella VJ. Lymphatic transport of drugs. Boca Raton: CRC; 1992.
14. Remaley AT, Warnick GR. Lipoprotein analysis. In: Meyers RA, editor. Encyclopedia of molecular cell biology and molecular medicine, vol. 7. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2005. p. 277-95.
15. CJH Porter SA Charman WN Charman 1996 Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion J Pharm Sci 85 351 6 10.1021/js950221g 1:CAS:528:DyaK28XhsFShsL0%3D 8901067 (Pubitemid 26105699)
16. CJH Porter SA Charman AJ Humberstone WN Charman 1996 Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion J Pharm Sci 85 357 61 10.1021/js9502229 1:CAS:528:DyaK28XhsFShsLo%3D 8901068 (Pubitemid 26105700)
17. S Khoo GA Edwards CJH Porter WN Charman 2001 A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine J Pharm Sci 90 1599 607 10.1002/jps.1110 1:CAS:528:DC%2BD3MXotVSru7g%3D 11745718 (Pubitemid 32979754)
18. SM Caliph WN Charman CJH Porter 2000 Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats J Pharm Sci 89 1073 84 10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V 1:CAS:528:DC%2BD3cXmtVWmsb4%3D 10906731
19. WN Charman VJ Stella 1986 Effect of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT Int J Pharm 33 165 72 10.1016/0378-5173(86)90050-5 1:CAS:528:DyaL2sXksFChtQ%3D%3D (Pubitemid 17197800)
20. P Gershkovich J Fanous B Qadri A Yacovan S Amselem A Hoffman 2009 The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons J Pharm Pharmacol 61 31 9 10.1211/jpp.61.01.0005 1:CAS:528:DC%2BD1MXhtlCisLs%3D 19126294
21. MM Hussain 2000 A proposed model for the assembly of chylomicrons Atherosclerosis 148 1 15 10.1016/S0021-9150(99)00397-4 1:STN:280: DC%2BD3c%2FkslKqsA%3D%3D 10580165
22. MM Hussain J Shi P Dreizen 2003 Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly J Lipid Res 44 22 32 10.1194/jlr.R200014-JLR200 1:CAS:528:DC%2BD3sXlslOhsg%3D%3D 12518019 (Pubitemid 36114766)
23. IJ Cartwright D Plonne JA Higgins 2000 Intracellular events in the assembly of chylomicrons in rabbit enterocytes J Lipid Res 41 1728 39 1:CAS:528:DC%2BD3cXotFahsr8%3D 11060342
24. A van Tol 2002 Phospholipid transfer protein Curr Opin Lipidol 13 135 9 10.1097/00041433-200204000-00004 11891415 (Pubitemid 34280764)
25. LJ Beamer 2003 Structure of human BPI (bactericidal/permeability- increasing protein) and implications for related proteins Biochem Soc Trans 31 791 4 10.1042/BST0310791 1:CAS:528:DC%2BD3sXlvFOmsrc%3D 12887307 (Pubitemid 36981129)
26. LJ Beamer D Fischer D Eisenberg 1998 Detecting distant relatives of mammalian LPS-binding and lipid transport proteins Protein Sci 7 1643 6 10.1002/pro.5560070721 1:CAS:528:DyaK1cXks1eqtbg%3D 9684900
27. X Qiu A Mistry MJ Ammirati BA Chrunyk RW Clark Y Cong, et al. 2007 Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules Nat Struct Mol Biol 14 106 13 10.1038/nsmb1197 17237796
28. XC Jiang Z Li R Liu XP Yang M Pan L Lagrost, et al. 2005 Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants J Biol Chem 280 18336 40 10.1074/jbc.M500007200 1:CAS:528:DC%2BD2MXjsl2ht7s%3D 15734742 (Pubitemid 41389080)
29. J Lie R de Crom T van Gent R van Haperen L Scheek I Lankhuizen, et al. 2002 Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion J Lipid Res 43 1875 80 10.1194/jlr.M200166-JLR200 1:CAS:528:DC%2BD38Xos1yht70%3D 12401886 (Pubitemid 35315805)
30. A Inazu K Nakajima T Nakano M Niimi MA Kawashiri A Nohara, et al. 2008 Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency Atherosclerosis 196 953 7 10.1016/j.atherosclerosis.2007.02.028 1:CAS:528:DC%2BD1cXhsVCitb0%3D 17399717
31. M Guerin W Le Goff E Duchene Z Julia T Nguyen T Thuren, et al. 2008 Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia Arterioscler Thromb Vasc Biol 28 148 54 10.1161/ATVBAHA.107.151688 1:CAS:528:DC%2BD2sXhsVeiu7nE 17951324
32. JS Millar ME Brousseau MR Diffenderfer PH Barrett FK Welty A Faruqi, et al. 2006 Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans Arterioscler Thromb Vasc Biol 26 1350 6 10.1161/01.ATV.0000219695.84644.56 1:CAS:528:DC%2BD28XksVGls7g%3D 16574893 (Pubitemid 44305381)
33. AG Salerno PR Patricio JA Berti HC Oliveira 2009 Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice Biochem J 419 629 34 10.1042/BJ20081299 1:CAS:528:DC%2BD1MXksVClsro%3D 19191759
34. L Izem RE Morton 2007 Possible role for intracellular cholesteryl ester transfer protein in adipocyte lipid metabolism and storage J Biol Chem 282 21856 65 10.1074/jbc.M701075200 1:CAS:528:DC%2BD2sXotVGmu78%3D 17522050 (Pubitemid 47195762)
35. V Guyard-Dangremont C Desrumaux P Gambert C Lallemant L Lagrost 1998 Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility Comp Biochem Physiol B Biochem Mol Biol 120 517 25 10.1016/S0305-0491(98)10038-X 1:STN:280:DyaK1M%2FgsVSkuw%3D%3D 9787811 (Pubitemid 28386764)
36. K Tsutsumi A Hagi Y Inoue 2001 The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals Biol Pharm Bull 24 579 81 10.1248/bpb.24.579 1:CAS:528:DC%2BD3MXjt1alt7k%3D 11379785 (Pubitemid 32499491)
37. CA Hogarth A Roy DL Ebert 2003 Genomic evidence for the absence of a functional cholesteryl ester transfer protein gene in mice and rats Comp Biochem Physiol B Biochem Mol Biol 135 219 29 10.1016/S1096-4959(03)00046-0 12798933 (Pubitemid 36694192)
38. NL Trevaskis CJH Porter WN Charman 2006 An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat Drug Metab Dispos 34 729 33 10.1124/dmd.105.008102 1:CAS:528:DC%2BD28Xks1Sks7s%3D 16467133